NVO Jul 2024 145.000 call
| Previous close | 1.5700 |
| Open | 1.9900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 145.00 |
| Expiry date | 2024-07-19 |
| Day's range | 1.4800 - 2.2300 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Yahoo FinanceNovo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
BenzingaWeight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
Online pharmacies and slimming clinics in Britain are reducing prices for Novo Nordisk A/S’s (NYSE:NVO) Wegovy and Eli Lilly And Co (NYSE:LLY) Mounjaro as initial supply shortages ease, a move driven by growing competition among retailers. The reduced prices at retailers like Simple Online Pharmacy, Mayfair Weight Loss Clinic, and London Slimming Clinic reflect the increasing demand for these weight-loss drugs. Simple Online Pharmacy, for instance, slashed the price of Mounjaro starter doses fro
